Haemonetics Corporation (HAE)
NYSE: HAE · Real-Time Price · USD
118.21
-1.72 (-1.43%)
Nov 9, 2026, 4:00 PM EST - Market closed
Haemonetics Income Statement
Financials in millions USD. Fiscal year is April - March.
Millions USD. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 26, 2026 | Mar '26 Mar 28, 2026 | Mar '25 Mar 29, 2025 | Mar '24 Mar 30, 2024 | Apr '23 Apr 1, 2023 | Apr '22 Apr 2, 2022 |
| 1,382 | 1,334 | 1,361 | 1,309 | 1,169 | 993.2 | |
Revenue Growth | 4.11% | -1.97% | 3.96% | 12.01% | 17.67% | 14.10% |
Cost of Revenue | 556.26 | 541.16 | 582.28 | 600.49 | 545.79 | 462.43 |
Gross Profit | 826.2 | 792.87 | 778.55 | 708.57 | 622.87 | 530.77 |
Selling, General & Admin | 461.84 | 438.54 | 422.05 | 418.82 | 373.95 | 332.2 |
Research & Development | 61.93 | 58.8 | 61.13 | 52.23 | 49.08 | 45.98 |
Amortization of Goodwill & Intangibles | 42.03 | 44 | 48.26 | 32.03 | 32.64 | 47.41 |
Operating Expenses | 565.81 | 541.34 | 531.45 | 503.08 | 455.67 | 425.6 |
Operating Income | 260.39 | 251.53 | 247.1 | 205.49 | 167.2 | 105.17 |
Interest Expense | -35 | -19.3 | -35.9 | -19.5 | -13 | -5.8 |
Currency Exchange Gain (Loss) | -4.67 | -5.11 | - | - | - | - |
Other Non Operating Income (Expenses) | -0.17 | -9.19 | 13.55 | 6.48 | -1.63 | -11.32 |
EBT Excluding Unusual Items | 220.55 | 217.93 | 224.75 | 192.47 | 152.57 | 88.05 |
Merger & Restructuring Charges | -7.36 | -10.13 | -45.91 | -30.19 | -11.55 | -28.82 |
Gain (Loss) on Sale of Investments | 4.9 | 4.9 | - | - | - | - |
Gain (Loss) on Sale of Assets | - | - | - | - | 0.38 | 9.6 |
Asset Writedown | -77.96 | -86.55 | -2.39 | -10.42 | - | -5.2 |
Other Unusual Items | 1.88 | 1.88 | 35.62 | - | - | - |
Pretax Income | 142.01 | 128.03 | 212.07 | 151.87 | 141.4 | 63.63 |
Income Tax Expense | 38.1 | 30.72 | 44.39 | 34.31 | 26 | 20.25 |
Net Income | 103.91 | 97.31 | 167.68 | 117.56 | 115.4 | 43.38 |
Net Income to Common | 103.91 | 97.31 | 167.68 | 117.56 | 115.4 | 43.38 |
Net Income Growth | -38.22% | -41.97% | 42.63% | 1.87% | 166.05% | -45.42% |
Shares Outstanding (Basic) | 46 | 47 | 50 | 51 | 51 | 51 |
Shares Outstanding (Diluted) | 46 | 47 | 51 | 51 | 51 | 51 |
Shares Change | -5.39% | -6.65% | -1.30% | -0.04% | 0.13% | 0.12% |
EPS (Basic) | 2.26 | 2.06 | 3.33 | 2.32 | 2.27 | 0.85 |
EPS (Diluted) | 2.24 | 2.05 | 3.31 | 2.29 | 2.24 | 0.84 |
EPS Growth | -34.84% | -38.07% | 44.54% | 2.23% | 166.67% | -45.81% |
Additional Metrics
Fiscal Year | TTM | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 26, 2026 | Mar '26 Mar 28, 2026 | Mar '25 Mar 29, 2025 | Mar '24 Mar 30, 2024 | Apr '23 Apr 1, 2023 | Apr '22 Apr 2, 2022 |
Free Cash Flow | 298.24 | 260.44 | 142.45 | 143.63 | 81.73 | 75.75 |
Free Cash Flow Per Share | 6.43 | 5.50 | 2.81 | 2.79 | 1.59 | 1.48 |
Gross Margin | 59.76% | 59.43% | 57.21% | 54.13% | 53.30% | 53.44% |
Operating Margin | 18.83% | 18.86% | 18.16% | 15.70% | 14.31% | 10.59% |
Profit Margin | 7.52% | 7.29% | 12.32% | 8.98% | 9.88% | 4.37% |
Free Cash Flow Margin | 21.57% | 19.52% | 10.47% | 10.97% | 6.99% | 7.63% |
EBITDA | 363.87 | 357.15 | 355.99 | 294.11 | 252.01 | 191.72 |
EBITDA Margin | 26.32% | 26.77% | 26.16% | 22.47% | 21.56% | 19.30% |
D&A For EBITDA | 103.48 | 105.62 | 108.89 | 88.62 | 84.81 | 86.55 |
EBIT | 260.39 | 251.53 | 247.1 | 205.49 | 167.2 | 105.17 |
EBIT Margin | 18.83% | 18.86% | 18.16% | 15.70% | 14.31% | 10.59% |
Effective Tax Rate | 26.83% | 24.00% | 20.93% | 22.59% | 18.39% | 31.83% |
Advertising Expenses | - | 7.4 | 7.7 | 7.1 | 7.2 | 4.4 |